Clinical trial NCT01222923: Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions
Official title: Single Dose Two-way Crossover Fed Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Risperidone fed study
Lead sponsor: Ranbaxy Inc.
Sponsor class: INDUSTRY
First posted: 2010-10-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.

Detailed description: A single dose two way crossover bioequivalence study in 40 normal healthy males and females was utilized to evaluate the pharmacokinetics and bioequivalence of Risperidone ODT (orally dissolving tablet) formulations. The test product was a 1 mg ODT tablet formulation of Risperidone manufactured by Ranbaxy Laboratories Ltd. The reference product was commercially available Risperidone 1 mg ODT tablets (Risperdal®), Janssen Pharmaceutica Products, LP. Each single oral dose (1 mg) will be administered orally as a 1 mg tablet. Blood samples were collected at intervals over a 72-hour period after medication administration. There was a washout period of 14 days between the two periods of the study.

Eligibility criteria: Inclusion Criteria:

1. Healthy subjects at least 18 years of age
2. Informed of the nature of the study and given written informed consent
3. Have a body weight within 15% of the appropriate range as defined in the 1983 Metropolitan Life Company tables weighing at least 110 pounds

Exclusion Criteria:

1. Hypersensitivity to risperidone (Risperdal®)
2. Any history of a clinical condition that might affect drug absorption, metabolism or excretion
3. Recent history (within one year) of mental illness, drug addiction, drug abuse or alcoholism
4. Donation of greater than 500 mg of blood in the past 4 weeks prior to study dosing or difficulty in donating blood
5. Received an investigational drug within the 4 weeks prior to study dosing
6. Currently taking any prescription medication, except for oral contraceptives, within the 7 days prior to the study dosing or over the counter medication within 3 days of study dosing. This prohibition does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications as judged by the attending physician
7. Regular smoking or more than 5 cigarettes daily or the daily use of nicotine-containing products beginning 3 months before the study medication administration through the final evaluation
8. If female the subject is lactating or has a positive pregnancy test at screening and prior to each of the treatment periods. Females of child-bearing potential must use a medically acceptable method of contraception throughout the study period and for one week after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/ or her partner are: oral contraceptives, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence. Females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication
9. Alcohol, grapefruit beverages or foods or caffeine beverages or foods beginning 1 days before each study medication administration through each study confinement period. Such restricted items include coffee, tea, iced tea, coke®, Pepsi®, mountain dew®, chocolate, brownies, etc.

Primary outcomes:
measure: Bioequivalence evaluation of risperidone 1 mg ODT tablets
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: aaiPharma Inc.
state: North Carolina
Study officials:
affiliation: AAIPharma
name: Evin H Sides III,, MD
role: PRINCIPAL_INVESTIGATOR
References: